Pacific Biosciences of California, Inc. (PACB): Price and Financial Metrics

Pacific Biosciences of California, Inc. (PACB)

Today's Latest Price: $33.55 USD

2.49 (8.02%)

Updated Jan 28 11:15am

Add PACB to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

PACB Stock Summary

  • The price/operating cash flow metric for Pacific Biosciences Of California Inc is higher than 98.85% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 70.24, Pacific Biosciences Of California Inc has a higher such ratio than 95.61% of stocks in our set.
  • The volatility of Pacific Biosciences Of California Inc's share price is greater than that of 97.99% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Pacific Biosciences Of California Inc, a group of peers worth examining would be ACAD, PSNL, GWPH, JG, and CERS.
  • Visit PACB's SEC page to see the company's official filings. To visit the company's web site, go to

PACB Stock Price Chart Interactive Chart >

Price chart for PACB

PACB Price/Volume Stats

Current price $33.55 52-week high $41.65
Prev. close $31.06 52-week low $2.20
Day low $31.15 Volume 1,438,360
Day high $34.04 Avg. volume 5,551,078
50-day MA $25.25 Dividend yield N/A
200-day MA $11.30 Market Cap 6.05B

Pacific Biosciences of California, Inc. (PACB) Company Bio

Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company was formerly known as Nanofluidics, Inc. The company was founded in 2000 and is based in Menlo Park, California.

PACB Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$33.55$0.02 -100%

We started the process of determining a valid price forecast for Pacific Biosciences Of California Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Pacific Biosciences Of California Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Pacific Biosciences Of California Inc ended up being:

  • As a business, PACB is generating more cash flow than only 18.61% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately only 5.92% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Pacific Biosciences Of California Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -47.28. This coverage rate is greater than that of only 2.71% of stocks we're observing for the purpose of forecasting via discounted cash flows.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Pacific Biosciences Of California Inc? See AGHC, ALC, AMRN, ATRS, and MOR.

PACB Latest News Stream

Event/Time News Detail
Loading, please wait...

PACB Latest Social Stream

Loading social stream, please wait...

View Full PACB Social Stream

Latest PACB News From Around the Web

Below are the latest news stories about Pacific Biosciences Of California Inc that investors may wish to consider to help them evaluate PACB as an investment opportunity.

Accuray (ARAY) Releases Encouraging Breast Cancer Study Results

Accuray (ARAY) releases positive data from a prospective trial of 338 women with low-risk breast cancer.

Yahoo | January 26, 2021

DNA Sequencing Market Growth Drivers, Trends, industry innovation demand analysis and Global Profit by 2030 | Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Macrogen, Inc., Pacific Biosciences of California, Inc., Bio-Rad Laborator

(Jan 2021 trend research report ) Latest research report on Market 2020 DNA Sequencing published by insightSLICE, starts with the market description, executive report, segmentation and classification. The report offers a comprehensive analysis of the market so that readers can

OpenPR | January 21, 2021

Global Next Generation Sequencing Market Opportunities and Strategies Report 2020-2030 Featuring Illumina, Thermo Fisher Scientific, Agilent Technologies, Pacific Biosciences of California & QIAGEN -

DUBLIN--(BUSINESS WIRE)--The "Next Generation Sequencing Global Market Opportunities and Strategies 2020-30: COVID-19 Impact and Recovery" report has been added to's offering. Next Generation Sequencing Global Market Opportunities and Strategies 2020-30: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global next generation sequencing market. The global next generation sequencing

Business Wire | January 14, 2021

Why Pacific Biosciences's Stock is Trading Higher Today

Pacific Biosciences's Stock Price And Volume Action Pacific Biosciences's (NASDAQ:PACB) stock has been rising Wednesday, up 6.84% to a price of …

Benzinga | January 13, 2021

Pacific Biosciences Reaches Our Price Target: Now What?

"This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. . In the daily Japanese candlestick chart of PACB, below, we can see that the shares corrected modestly after our Dec. 9 review and subsequently rallied to the $39 price target. This chart shows that prices are above the rising 50-day moving average line and trade at more than three times the level of the rising 200-day moving average line.

Yahoo | January 13, 2021

Read More 'PACB' Stories Here

PACB Price Returns

1-mo 32.19%
3-mo 155.91%
6-mo 799.46%
1-year 609.30%
3-year 1,005.44%
5-year 213.84%
YTD 29.34%
2020 404.67%
2019 -30.54%
2018 180.30%
2017 -30.53%
2016 -71.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8361 seconds.